Home›Research›Compare›CJC-1295 (without DAC) vs Ipamorelin
Peptide ComparisonCJC-1295 (without DAC) vs Ipamorelin
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC 1295
Half-life: ~30 minutes
454 providers listed
Ipamorelin
NNC 26-0161
Half-life: 2 hours
463 providers listed
Ipamorelin has a longer half-life than CJC-1295 (without DAC), so it generally needs less frequent dosing.
CJC-1295 (without DAC)
Half-life
~30 minutes
Ipamorelin
Half-life
2 hours
| Your goal | Better option |
|---|---|
| Extended GH elevation via longer half-life | CJC-1295 (without DAC) |
| Fewer injections needed per week (DAC variant) | CJC-1295 (without DAC) |
| More selective GH pulse (minimal cortisol/prolactin impact in research) | Ipamorelin |
| GHRP mechanism — different pathway from GHRH analogs | Ipamorelin |
| More provider options (454 vs 463) | Ipamorelin |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
Ipamorelin
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
Ipamorelin
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the managem…
GH secretagogues increase bone mineral content in adult female rats
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
+1 more
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About Ipamorelin
Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceIpamorelin
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCommonly stacked
Well DocumentedCJC-1295 (without DAC) and Ipamorelin are reported to work together. Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
Ipamorelin
CJC-1295
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
Sermorelin
Research suggests Sermorelin and Ipamorelin may produce complementary growth hormone release effects when combined. Sermorelin acts as a GHRH analogue via pituitary receptors, while Ipamorelin acts via ghrelin receptors — dual-pathway stimulation studied in GH optimization research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
Ipamorelin
Where to source these peptides
CJC-1295 (without DAC)
454 listed
Browse directory →
Providers offeringIpamorelin
463 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs Ipamorelin — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/ipamorelin